



**Proteomics International**

LABORATORIES LTD

**ASX Release  
23 October 2026**

**ASX code: PIQ**

## **National rollout of Promarker®D and Promarker®Eso to commence on 26 October 2026**

### **Highlights**

- National rollout of Promarker D and Promarker Eso through Healix, Proteomics International's exclusive Australian pathology distribution partner, scheduled to commence on Monday, 26 October 2026.
- Field sales teams have completed training in both tests, with joint sales and marketing plans agreed to support clinician education, awareness and appropriate referrals.
- Systems and operational integration will enable patient blood collection and payment through Healix collection centres.
- National rollout of Promarker D and Promarker Eso experience to support commercial release of Promarker®Endo in FY27 Q3 (January–March 2027), subject to clinical deployment and applicable quality, accreditation and regulatory requirements.

Proteomics International Laboratories Ltd (ASX: PIQ) ("Proteomics International" or "the Company") is pleased to announce that the national rollout of Promarker D and Promarker Eso blood tests, in collaboration with Healix Limited (ASX: HLS) ("Healix"), is scheduled to commence on Monday, 26 October 2026.

The national rollout builds on the experience of the controlled market release via the Helix network in Western Australia and the Northern Territory, announced on 14 September 2026. It represents the next phase of the rollout plan, significantly expanding the availability of the tests across Australia.

### **National rollout readiness**

Field sales teams have completed training on the Promarker D and Promarker Eso blood tests, including their intended clinical uses and the processes for accessing the tests. This prepares the teams to engage with general practitioners and relevant specialists as national rollout commences.

Proteomics International and Healix have also agreed joint sales and marketing plans to build clinician awareness, provide education and support appropriate referrals and patient access.

Integration of systems and operational processes will be enabled to go-live on Monday, 26 October 2026. From that date, Healix collection centres are expected to accept patients for blood collection and process payments.

The tests will initially be available on a private-pay basis at the previously announced Australian patient prices of \$495 for Promarker D and \$997 for Promarker Eso.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Proteomics International will continue to perform laboratory testing in its NATA accredited facility, and provide clinical reporting, scientific and medical support, and quality and regulatory compliance. Healius will support specimen collection, pathology distribution and clinician engagement through its national infrastructure.

### **Management commentary**

#### **Proteomics International CEO and Managing Director, David Morris, said:**

“National rollout is a significant milestone in bringing our Promarker portfolio to Australian clinicians and patients. With national field sales teams and collection centre staff trained and joint sales and marketing plans agreed, our focus is on completing integration and supporting clinicians in understanding how these tests can contribute to patient assessment and management.

“The collection pathways, systems and clinician relationships established through this rollout are also expected to provide a strong foundation for the planned introduction of PromarkerEndo, once it is available.”

#### **Healium Group Executive – Customer & Commercial, Anthea Muir, said:**

“This rollout brings together Healium’s national collection network and clinician relationships with Proteomics International’s specialist testing capability, broadening access to the Promarker portfolio.

“We look forward to supporting referring clinicians and patients as Promarker D and Promarker Eso become available nationally.”

### **Preparing for Promarker Endo commercial release**

As announced on 13 October 2026, Proteomics International has completed refinement and independent validation of the model underpinning its Promarker Endo blood test for endometriosis.

The Company expects to make Promarker Endo commercially available during FY27 Q3 (January–March 2027).

The systems, specimen collection processes and clinician engagement activities established for Promarker D and Promarker Eso, together with operational experience gained during national rollout, are expected to support preparations for the introduction of Promarker Endo through the Healium distribution partnership.

### **Commercial outlook**

The national rollout establishes broader access to Promarker D and Promarker Eso through an existing pathology distribution network.

As the Promarker portfolio remains at an early stage of commercialisation, revenue under the distribution agreement cannot be reliably estimated at this time. The Company will update the market on material developments in accordance with its continuous disclosure obligations.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

**– ENDS –**

**About Proteomics International Laboratories Ltd**

Proteomics International is a Perth-based medical technology company specialising in proteomics, the study of proteins and their functions. The Company develops precision diagnostic tests and provides specialist bioanalytical services to improve the detection and management of disease.

**For further information please contact**

David Morris  
CEO and Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Jane Lowe  
Investor Relations  
IR Department  
T: +61 411 117 774  
E: [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

**Forward Looking Statements**

This announcement contains forward-looking statements regarding future events and the future performance of Proteomics International. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied.

Commercial outcomes may depend on factors including implementation timing, clinician adoption, patient utilisation, reimbursement pathways, regulatory requirements where applicable, study outcomes and prevailing market conditions.

These statements are based on information available to the Company as at the date of this announcement and should not be relied upon as guarantees of future performance. Except as required by law, the Company undertakes no obligation to update any forward-looking statements.